GP Pharm, S.A. Sustainability Profile
GP Pharm, S.A., a prominent player in the pharmaceutical industry, is headquartered in Spain and operates extensively across Europe and Latin America. Founded in 2000, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. With a diverse portfolio that includes injectable medications, GP Pharm is renowned for its commitment to innovation and quality assurance. The company’s state-of-the-art facilities and rigorous compliance with international standards set it apart in a competitive market. Notable achievements include a robust pipeline of products that cater to various therapeutic areas, positioning GP Pharm as a trusted partner in healthcare. Through its dedication to excellence, GP Pharm continues to enhance patient outcomes and contribute significantly to the global pharmaceutical landscape.
DitchCarbon Score
How does GP Pharm, S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GP Pharm, S.A.'s score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GP Pharm, S.A.'s reported carbon emissions
GP Pharm, S.A., headquartered in Spain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Berkshire Hathaway Inc., which may influence its climate commitments and reporting practices. While GP Pharm has not established its own reduction targets or climate pledges, it is important to note that it inherits certain sustainability initiatives from its parent company, Berkshire Hathaway Inc. This includes participation in the Carbon Disclosure Project (CDP) and Climate Action 100+ (CA100), which are significant frameworks aimed at enhancing corporate climate accountability and reducing greenhouse gas emissions. As of now, GP Pharm's climate commitments and specific emissions data remain unspecified, reflecting a broader context within the industry where many companies are still developing their sustainability strategies.
How Carbon Intensive is GP Pharm, S.A.'s Industry?
How Carbon Intensive is GP Pharm, S.A.'s Location?
GP Pharm, S.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GP Pharm, S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
